Young-Su Noh

发表

Caffeoyloxy-5,6-dihydro-4-methyl-(2H)-pyran-2-one isolated from the leaves of Olinia usambarensis attenuates LPS-induced inflammatory mediators by inactivating AP-1 and NF-κB.

Y. Jang, Kyung-Tae Lee, Ji-Sun Shin, 2019, Chemico-biological interactions.

Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study

Kyung-Tae Lee, Young-Su Noh, E. Chung, 2017, Translational and clinical pharmacology.

Anti-inflammatory Effects of the Methanol Extract of Polytrichum Commune via NF-κB Inactivation in RAW 264.7 Macrophage Cells

Kyung-Tae Lee, Ji-Sun Shin, Jung-Hwan Nam, 2008 .

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Tae Won Kim, Jeeyun Lee, Hyeong-Seok Lim, 2019, Journal of Clinical Oncology.

Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis.

Ji-Sun Shin, Eu-jin Cho, Young-Wuk Cho, 2011, Journal of ethnopharmacology.

Arvelexin from Brassica rapa suppresses NF‐κB‐regulated pro‐inflammatory gene expression by inhibiting activation of IκB kinase

Ji-Sun Shin, Myung‐Sook Choi, Young-Wuk Cho, 2011, British journal of pharmacology.

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Z. Modrušan, Tae Won Kim, Matthew T. Chang, 2021, Nature.

A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third‐generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers

K. Lee, I. Jang, Seonghae Yoon, 2019, Basic & clinical pharmacology & toxicology.

Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

Keunchil Park, E. Felip, Dong-Wan Kim, 2021, Cancer.

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.

Keunchil Park, E. Cho, Dong-Wan Kim, 2019, Lung cancer.

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

N. Daver, C. Jung, M. Arellano, 2020 .

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

K. Seo, N. Daver, C. Jung, 2019, Blood.

Arvelexin from Brassica rapa suppresses NF‐κB‐regulated pro‐inflammatory gene expression by inhibiting activation of IκB kinase

Ji-Sun Shin, Myung‐Sook Choi, Young-Wuk Cho, 2011, British journal of pharmacology.

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

Dae-Ho Lee, Jeeyun Lee, S. Monemi, 2021 .

Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis.

Ji-Sun Shin, Eu-jin Cho, Young-Wuk Cho, 2011, Journal of ethnopharmacology.